| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
EXEL
Exelixis
|
Sep 04, 2025 | BUY |
Strong Buy
-21.0% avg upside
33 analysts
|
$56.00
7.91% Upside
|
+42.1% |
|
COGT
Cogent Biosciences
|
Sep 04, 2025 | BUY |
Strong Buy
+7.1% avg upside
26 analysts
|
$22.00
36.37% Downside
|
+164.5% |
|
IONS
Ionis Pharmaceuticals
|
Sep 04, 2025 | BUY |
Strong Buy
+13.3% avg upside
43 analysts
|
$84.00
13.36% Upside
|
+23.5% |
|
CYTK
Cytokinetics
|
Sep 03, 2025 | BUY |
Strong Buy
+8.9% avg upside
36 analysts
|
$84.00
6.53% Upside
|
+58.0% |
|
ARWR
Arrowhead Pharmaceuticals
|
Sep 03, 2025 | HOLD |
Strong Buy
-19.2% avg upside
26 analysts
|
$17.00
79.19% Downside
|
+168.1% |
|
ALNY
Alnylam Pharma
|
Sep 02, 2025 | BUY |
Strong Buy
+23.6% avg upside
51 analysts
|
$583.00
109.69% Upside
|
-36.7% |
|
BBIO
BridgeBio Pharma
|
Sep 01, 2025 | BUY |
Strong Buy
+38.7% avg upside
34 analysts
|
$67.00
1.01% Upside
|
+34.8% |
|
VKTX
Viking Therapeutics
|
Aug 20, 2025 | HOLD |
Strong Buy
+141.1% avg upside
30 analysts
|
$29.00
4.49% Downside
|
+15.4% |
|
CLDX
Celldex
|
Aug 20, 2025 | BUY |
Strong Buy
+20.6% avg upside
28 analysts
|
$48.00
47.99% Upside
|
+54.9% |
|
MDGL
Madrigal Pharmaceuticals
|
Aug 19, 2025 | BUY |
Strong Buy
-5.8% avg upside
31 analysts
|
$505.00
0.17% Downside
|
+26.7% |
|
MIRM
Mirum Pharmaceuticals
|
Aug 18, 2025 | BUY |
Strong Buy
+7.0% avg upside
21 analysts
|
$89.00
16.85% Downside
|
+60.7% |
|
SDGR
Schrodinger
|
Aug 15, 2025 | HOLD |
Strong Buy
+79.8% avg upside
14 analysts
|
$20.00
26.95% Upside
|
-25.4% |
|
PLRX
Pliant Therapeutics
|
Aug 11, 2025 | HOLD |
Buy
+1821.1% avg upside
21 analysts
|
$1.70
46.55% Upside
|
-27.7% |
|
CRNX
Crinetics Pharmaceuticals
|
Aug 08, 2025 | BUY |
Strong Buy
+121.2% avg upside
20 analysts
|
$60.00
67.36% Upside
|
+24.0% |
|
NTLA
Intellia Therapeutics
|
Aug 08, 2025 | HOLD |
Buy
+151.9% avg upside
37 analysts
|
$12.00
23.45% Downside
|
+12.2% |
|
ASND
Ascendis Pharma
|
Aug 07, 2025 | BUY |
Strong Buy
+17.0% avg upside
24 analysts
|
$290.00
25.59% Upside
|
+21.4% |
|
INCY
Incyte
|
Jul 30, 2025 | BUY |
Buy
+1.0% avg upside
47 analysts
|
$103.00
4.89% Upside
|
+27.7% |
|
BMRN
BioMarin Pharmaceutical
|
May 01, 2025 | HOLD |
Strong Buy
+72.8% avg upside
52 analysts
|
$78.00
42.62% Upside
|
-13.8% |
|
PTCT
PTC Therapeutics
|
Feb 11, 2025 | SELL |
Buy
-1.5% avg upside
29 analysts
|
$45.00
43.08% Downside
|
-45.8% |
|
AKBA
Akebia Therapeutics
|
Nov 05, 2021 | HOLD |
Strong Buy
+822.0% avg upside
16 analysts
|
$2.75
157.04% Upside
|
-90.8% |
|
IRWD
Ironwood Pharma
|
Oct 12, 2021 | HOLD |
Hold
+235.6% avg upside
23 analysts
|
$14.00
295.58% Upside
|
-26.8% |
|
TECX
Tectonic Therapeutic
|
Oct 12, 2021 | BUY |
Strong Buy
+88.0% avg upside
24 analysts
|
$25.00
16.63% Downside
|
-89.4% |
|
SNDX
Syndax Pharmaceuticals
|
Oct 12, 2021 | HOLD |
Strong Buy
+88.8% avg upside
27 analysts
|
$21.00
10.52% Upside
|
+35.3% |
|
KPTI
Karyopharm Therapeutics
|
Oct 12, 2021 | BUY |
Strong Buy
+147.4% avg upside
18 analysts
|
$27.00
199.41% Upside
|
-12.3% |
|
IMRX
Immuneering
|
Aug 24, 2021 | HOLD |
Strong Buy
+303.9% avg upside
10 analysts
|
$39.00
784.44% Upside
|
-76.2% |
|
RYTM
Rhythm Pharmaceuticals
|
Aug 03, 2021 | BUY |
Strong Buy
+25.2% avg upside
19 analysts
|
$54.00
44.17% Downside
|
+5.4% |
|
ARQT
Arcutis Biotherapeutics
|
Jul 16, 2021 | BUY |
Strong Buy
+49.6% avg upside
14 analysts
|
$50.00
90.79% Upside
|
-5.5% |
|
MGNX
MacroGenics
|
Apr 30, 2021 | SELL |
Buy
+326.2% avg upside
25 analysts
|
$17.00
311.71% Upside
|
+77.9% |
|
NBRVF
Nabriva Therapeutics
|
Dec 07, 2020 | HOLD |
Buy
+13374900.0% avg upside
9 analysts
|
$20.00
19999899.92% Upside
|
· |
|
SRPT
Sarepta Therapeutics
|
Oct 02, 2017 | BUY |
Buy
+244.5% avg upside
49 analysts
|
$60.00
242.36% Upside
|
+187.4% |
|
VRTX
Vertex Pharmaceuticals
|
Jan 09, 2015 | HOLD |
Strong Buy
-2.6% avg upside
61 analysts
|
$126.00
72.15% Downside
|
-9.4% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.